FDA Updates Kaletra Labeling
"The Kaletra (lopinavir/ritonavir) product labeling was updated to include drug-drug interaction information with etravirine, rilpivirine and simeprevir and to update the Use in Specific Populations, Pediatric Use subsection with information from a clinical trial that investigated the use of a once daily dosing regimen."
The updated labeling will be available soon at the FDA website.
More information is available:
FDA: Press release
AIDSinfo: Patient fact sheet on Kaletra
Source: AIDSinfo At-a-Glance: Offering Information on HIV/AIDS Treatment, Prevention, and Research, A Service of the U.S. Department of Health and Human Services (DHHS) - Category: Infectious Diseases Source Type: news
More News: Clinical Trials | Department of Health | Health | HIV AIDS | Infectious Diseases | Kaletra | Norvir | Pediatrics | Websites